Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 2
2018 5
2019 6
2021 2
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection.
Barmada A, Handfield LF, Godoy-Tena G, de la Calle-Fabregat C, Ciudad L, Arutyunyan A, Andrés-León E, Hoo R, Porter T, Oszlanczi A, Richardson L, Calero-Nieto FJ, Wilson NK, Marchese D, Sancho-Serra C, Carrillo J, Presas-Rodríguez S, Ramo-Tello C, Ruiz-Sanmartin A, Ferrer R, Ruiz-Rodriguez JC, Martínez-Gallo M, Munera-Campos M, Carrascosa JM, Göttgens B, Heyn H, Prigmore E, Casafont-Solé I, Solanich X, Sánchez-Cerrillo I, González-Álvaro I, Raimondo MG, Ramming A, Martin J, Martínez-Cáceres E, Ballestar E, Vento-Tormo R, Rodríguez-Ubreva J. Barmada A, et al. Among authors: presas rodriguez s. Eur J Immunol. 2024 Jan;54(1):e2350633. doi: 10.1002/eji.202350633. Epub 2023 Oct 20. Eur J Immunol. 2024. PMID: 37799110
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE, Prieto González JM, Caminero Rodríguez AB, Olascoaga Urtaza J, Alonso AM, Durán Ferreras E, Espinosa R, Dotor J, Romera M, Ares Luque A, Pérez Ruiz D, Calles C, Hernández MA, Hervás García M, Mendoza Rodríguez A, Berdei Montero Y, Téllez N, Herrera Varó N, Sotoca J, Presas-Rodríguez S, Querol Gutierrez LA, Hervás Pujol M, Batlle Nadal J, Martín Ozaeta G, Gubieras Lillo L, Martínez Yélamos S, Ramió-Torrentà L, Mallada Frechin J, Belenguer Benavides A, Gascón-Giménez F, Casanova B, Landete Pascual L, Berenguer L, Navarro L, Gómez Gutierrez M, Durán C, Rodríguez Regal A, Álvarez E, García-Estévez DA, López Real AM, Llaneza González MA, Marzo Sola ME, Sánchez-Menoyo JL, Oterino A, Villaverde González R, Castillo-Triviño T, Álvarez de Arcaya A, Llarena C. Meca-Lallana JE, et al. Among authors: presas rodriguez s. Neurol Ther. 2023 Dec;12(6):2177-2193. doi: 10.1007/s40120-023-00557-7. Epub 2023 Oct 20. Neurol Ther. 2023. PMID: 37861931 Free PMC article.
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Sancho-Saldaña A, Gil Sánchez A, Quirant-Sánchez B, Nogueras L, Peralta S, Solana MJ, González-Mingot C, Gallego Y, Quibus L, Ramo-Tello C, Presas-Rodríguez S, Martínez-Cáceres E, Torres P, Hervás JV, Valls J, Brieva L. Sancho-Saldaña A, et al. Among authors: presas rodriguez s. J Clin Med. 2022 Apr 29;11(9):2509. doi: 10.3390/jcm11092509. J Clin Med. 2022. PMID: 35566632 Free PMC article.
Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab.
Granell-Geli J, Izquierdo-Gracia C, Sellés-Rius A, Teniente-Serra A, Presas-Rodríguez S, Mansilla MJ, Brieva L, Sotoca J, Mañé-Martínez MA, Moral E, Bragado I, Goelz S, Martínez-Cáceres E, Ramo-Tello C. Granell-Geli J, et al. Among authors: presas rodriguez s. J Pers Med. 2021 Dec 10;11(12):1347. doi: 10.3390/jpm11121347. J Pers Med. 2021. PMID: 34945819 Free PMC article.
Toxic and nutritional factors trigger Leber hereditary optic neuropathy due to a mitochondrial tRNA mutation.
Vela-Sebastián A, López-Gallardo E, Emperador S, Hernández-Ainsa C, Pacheu-Grau D, Blanco I, Ros A, Pascual-Benito E, Rabaneda-Lombarte N, Presas-Rodríguez S, García-Robles P, Montoya J, Ruiz-Pesini E. Vela-Sebastián A, et al. Among authors: presas rodriguez s. Clin Genet. 2022 Oct;102(4):339-344. doi: 10.1111/cge.14189. Epub 2022 Jul 18. Clin Genet. 2022. PMID: 35808913 Free PMC article.
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
Quirant-Sánchez B, Hervás-García JV, Teniente-Serra A, Brieva L, Moral-Torres E, Cano A, Munteis E, Mansilla MJ, Presas-Rodriguez S, Navarro-Barriuso J, Ramo-Tello C, Martínez-Cáceres EM. Quirant-Sánchez B, et al. Among authors: presas rodriguez s. CNS Neurosci Ther. 2018 Dec;24(12):1175-1184. doi: 10.1111/cns.12851. Epub 2018 Apr 15. CNS Neurosci Ther. 2018. PMID: 29656444 Free PMC article.
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
Sancho-Saldaña A, Gil-Sánchez A, González-Mingot C, Peralta S, Solana MJ, Torres P, Juanes A, Quibus L, Ruiz E, Sanpedro E, Quirant-Sánchez B, Martínez-Cáceres E, Ramo Tello C, Presas-Rodríguez S, García Rubio S, Baron BP, Ramió-Torrentà L, Sotoca J, González-Suárez I, Eichau S, Prieto-González JM, Blasco Quilez MR, Sabín-Muñoz J, Sánchez-López AJ, Llorens Calatayud G, Calles C, Sempere ÁP, Garcés M, Carmona O, Moral E, Hervás JV, Blanco Y, Sola-Valls N, Tellez Lara N, Forero L, Brieva L. Sancho-Saldaña A, et al. Among authors: presas rodriguez s. J Clin Med. 2023 Nov 23;12(23):7243. doi: 10.3390/jcm12237243. J Clin Med. 2023. PMID: 38068295 Free PMC article.
20 results